Angiotensin Receptor Enkephalinase Inhibitor On Effects Of ECG Indexes And Cardiac Function In Patients With Chronic Heart Failure

【Objective】To investigate the effect of angiotensin receptor enkephalinase inhibitor on ECG indexes and cardiac function in patients with chronic heart failure.【Methods】From October 2019 to June 2021,50 patients with chronic heart failure were selected for treatment in the Bengbu Third People’s hospital.According to the patients’ condition,they need to be treated with conventional anti heart failure drugs.On this basis,they apply angiotensin receptor enkephalinase inhibitor（sacubatrovalsartan sodium,Novartis pharmaceutical,Guoyao zhunzzi j20190002）,and record the differences between the dosage,ECG index,cardiac function grade,plasma amino terminal precursor brain natriuretic peptide,left ventricular ejection fraction and myocardial remodeling index before and 6 months after the use of sacubatrovalsartan,And adverse drug reaction events.【Results】A total of 50 patients were included in this experiment,all of whom completed the experiment.There were 27 males and 23 females,aged 47 ～ 79（64.64±8.30）years,the length of hospital stay was（10.42±2.94）days,and the classification of cardiac function:15 cases of grade II,27 cases of grade III and 8 cases of grade IV.The comparison of general data conforms to the normal distribution.（1）ECG index: compared with that before treatment,QTc,QTd,TP-Tec interval and QRS wave time limit decreased significantly after treatment（P < 0.01）.Record the number of cases of ventricular septal q wave of ECG before and after treatment: 25 cases had ventricular septal q waves before treatment and 30 cases had ventricular septal q waves after treatment.There was significant difference before and after treatment（P = 0.025）（2）cardiac function: the grade of cardiac function increased significantly and the clinical symptoms improved.Left ventricular ejection fraction（LVEF）was significantly higher than that before treatment（P < 0.01）,and NT Pro BNP,left ventricular end diastolic diameter（LVEDD）and left ventricular end systolic diameter（LVESD）were lower than that before treatment（P < 0.01）.（3）During the follow-up period of 6 months,5 patients were rehospitalized,and the rehospitalization rate was 10.0%.There were 2 cases of hypotension and 1 case of hyperkalemia.There were no serious renal failure and hyperkalemia events.【Conclusion】1.ARNI can significantly reduce the QRS wave duration,QTc interval,QTd dispersion and TP-Tec interval of ECG in patients with chronic heart failure.At the same time,it can improve the number of Q-wave deletion in ventricular septum,which may reduce the occurrence of ventricular arrhythmia and improve the prognosis of patients.2.ARNI can improve cardiac function,inhibit ventricular remodeling and improve the quality of life of patients with chronic heart failure,and there are no obvious adverse reactions in the process of treatment.